Noradrenaline Kabi (Noradrenaline Tartrate)

Noradrenaline Tartrate, the active ingredient in Noradrenaline Kabi, is a sympathomimetic presented as a sterile solution for intravenous use. It functions as a potent vasopressor to increase systemic vascular resistance and raise arterial pressure in patients experiencing acute hypotension, such as those with septic shock or cardiogenic shock.

GNH USA supplies Noradrenaline Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet critical care needs.

Noradrenaline Kabi is used as a vasopressor in the management of acute circulatory failure.

- Septic shock: restores vascular tone and improves blood pressure in patients with severe infection‑induced hypotension. - Cardiogenic shock: supports cardiac output by increasing systemic vascular resistance in heart‑failure related hypotension. - Peri‑operative hypotension: maintains arterial pressure during anesthesia and surgical procedures. - Post‑cardiac arrest care: helps sustain perfusion pressure during early resuscitation phases.

Noradrenaline Kabi may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often related to rapid blood pressure changes. - Tachycardia: increased heart rate due to beta‑1 stimulation. - Peripheral ischemia: reduced blood flow to extremities causing coldness or pain. - Arrhythmias: irregular heart rhythms, especially at high infusion rates. - Nausea: gastrointestinal discomfort during infusion. - Anxiety: feelings of nervousness or restlessness.

Serious or Rare Side Effects: - Severe hypertension: dangerously high blood pressure requiring immediate intervention. - Myocardial ischemia: reduced heart muscle oxygenation leading to chest pain or infarction. - Limb necrosis: tissue death from prolonged vasoconstriction. - Pulmonary edema: fluid accumulation in lungs due to increased afterload. - Seizures: rare neurologic events linked to extreme catecholamine excess. - Fatal cardiovascular collapse: rare but possible if dosing is inappropriate.

When using Noradrenaline Kabi, clinicians should observe several safety measures.

- Dose titration: adjust infusion rate to achieve target blood pressure while avoiding overshoot. - Cardiac monitoring: continuous ECG and hemodynamic monitoring are essential. - Peripheral perfusion: assess limb circulation frequently to detect ischemia. - Fluid status: ensure adequate intravascular volume before initiation. - Drug compatibility: verify compatibility with other IV solutions before mixing. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenaline Kabi can interact with other agents that affect cardiovascular tone or catecholamine metabolism.

Major Interactions (Avoid): - Beta‑blockers: may blunt the desired increase in heart rate and contractility. - MAO inhibitors: can potentiate hypertensive effects leading to severe hypertension. - Tricyclic antidepressants: increase risk of arrhythmias when combined.

Moderate Interactions (Monitor Closely): - Vasodilators (e.g., nitroglycerin): may require higher norepinephrine doses. - Calcium channel blockers: can enhance hypotensive episodes if norepinephrine is insufficient. - Diuretics: may exacerbate intravascular volume depletion, affecting response.